Valuation: Ardelyx, Inc.

Market Cap 767M 685M 632M 574M 1.07B 72.87B 1.09B 7.62B 3.01B 38.14B 2.88B 2.82B 120B P/E 2026 *
-17.5x
P/E 2027 * 13.7x
Enterprise Value 767M 685M 632M 574M 1.07B 72.87B 1.09B 7.62B 3.01B 38.14B 2.88B 2.82B 120B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.23x
Free-Float
95.99%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-0.32%
Current month-9.94%
1 month-11.49%
3 months-39.96%
6 months-48.32%
Current year-47.17%
1 week 3.02
Extreme 3.02
3.25
1 month 3.02
Extreme 3.02
3.48
Current year 3.02
Extreme 3.02
8.4
1 year 3.02
Extreme 3.02
8.4
3 years 3.02
Extreme 3.02
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 2009-02-28
Director of Finance/CFO 55 2025-11-03
Chief Tech/Sci/R&D Officer 50 2026-03-31
Director TitleAgeSince
Director/Board Member 61 2009-02-28
Chairman 60 2014-02-28
Director/Board Member 59 2014-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Sell

Chief Financial Officer

-1,558 0.0006%
8/21/26 Sell

Controller/Auditor

-3,982 0.0016%
8/21/26 Sell

Head of Human Resources

-15,136 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-0.32%-39.13%-10.98% 767M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.13%+2.14%+40.64%+140.70% 38.39B
Weighted average by Cap. +0.38%+2.72%+47.40%+158.24%

Financials

2026 *2027 *
Net sales 487M 435M 401M 364M 682M 46.25B 693M 4.83B 1.91B 24.21B 1.83B 1.79B 76.39B 624M 557M 514M 467M 874M 59.25B 887M 6.19B 2.45B 31.01B 2.34B 2.29B 97.86B
Net income -44.04M -39.31M -36.29M -32.93M -61.67M -4.18B -62.61M -437M -173M -2.19B -165M -162M -6.91B 60.5M 54.02M 49.86M 45.25M 84.73M 5.74B 86.03M 600M 238M 3.01B 227M 222M 9.49B
Net Debt - -
Projected Income Statement - Annual - Ardelyx, Inc.
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
26-10-23 US$3.080 -3.75% 4,816,848
26-10-22 US$3.200 +2.24% 2,723,800
26-10-21 US$3.130 -2.49% 3,017,464
26-10-20 US$3.210 +3.88% 3,964,190
26-10-19 US$3.090 0.00% 3,227,276
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ardelyx, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.080USD
Average target price
12.80USD
Spread / Average Target
+315.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ardelyx, Inc.
  1. Stock Market
  2. Stocks
  3. ARDX Stock